Pain Research and Management / 2019 / Article / Tab 2

Research Article

A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy

Table 2

Baseline demographics/etiologies between total sample and study sample.

Sample population (n = 1841)Sample with ≥2 VAS reduction at 7 days (n = 1143)Sample with <2 VAS reduction at 7 days (n = 698)Sample with ≥2 VAS reduction at 7 days + “definitely purchase” (n = 682)Sample with ≥2 VAS reduction at 7-days + “not definitely purchase” (n = 461)Study sample (n = 240)

Demographics
Age (years)55.654.454.356.456.357.9
Duration of pain (years)6.46.56.26.46.66.5
Women66%70%61%71%69%70%
Pain > than 6 months89%89%88%90%88%91%
Baseline VAS8.028.177.778.268.028.23
7-day treatment VAS5.033.387.722.973.972.82
% pain reduction33%59%0%64%51%66%
VAS ≥2 reduction62%100%0%100%100%100%
VAS ≥3 reduction54%87%0%94%77%97%
% “definitely purchase” intent38%60%3%100%0%100%
Pain etiology
Osteoarthritis30%31%28%33%26%25%
Rheumatoid arthritis15%15%14%15%15%7%
Fibromyalgia10%10%9%10%11%20%
Sports injury8%8%7%8%8%12%
Neuropathy5%5%5%5%5%8%
Surgery6%6%5%6%6%6%
Tendinitis3%3%3%3%2%4%
Other23%22%29%20%27%18%

Subjects often reported pain in multiple areas of the body, but this designation was predominantly for the back (49%), followed by knee (27%), shoulder (17%), hip (16%), neck (8%), and others (11%). The rank ordering of the locations where the PSWT medical device was applied mirrored the rank order of reported locations of pain.